Page last updated: 2024-08-24

aromasil and tamoxifen

aromasil has been researched along with tamoxifen in 285 studies

Research

Studies (285)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (1.05)	18.2507
2000's	129 (45.26)	29.6817
2010's	143 (50.18)	24.3611
2020's	10 (3.51)	2.80

Authors

Authors	Studies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Di Salle, E; Giudici, D; Zaccheo, T	1
Engan, T; Johannessen, DC; Krane, J; Kvinnsland, S; Lønning, PE	1
Harvey, HA; Santen, RJ	1
Arkhipov, A; Bajetta, E; Cervek, J; di Salle, E; Dirix, LY; Dugardyn, JL; Fein, LE; Fowst, C; Jones, SE; Kaufmann, M; Massimini, G; Mennel, RG; Miller, LL; Nasurdi, C; Piscitelli, G; Polli, A; Zilembo, N	1
Anker, G; Bonneterre, J; di Salle, E; Dirix, LY; Kvinnsland, S; Lobelle, JP; Mariani, O; Massimini, G; Polli, A; Prove, AM; Wilking, N	1
Bajetta, E; Cervek, J; Di Salle, E; Dirix, LY; Fein, LE; Fowst, C; Jones, SE; Kaufmann, M; Massimini, G; Piscitelli, G; Polli, A	1
Mamounas, EP	1
Lønning, PE	1
Murray, R	1
Nabholtz, JM; Reese, DM	1
Dickler, MN; Norton, L	1
Buzdar, AU	2
Goss, PE	1
Beex, L; Biganzoli, L; Cufer, T; Dirix, L; Duchateau, L; Lobelle, JP; Lohrisch, C; Nooij, M; Paridaens, R; Piccart, M; Van Hoorebeeck, I	1
Jones, SE	2
Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R	1
Ingle, JN	4
Robertson, JF	1
Rose, C	1
Brodie, AH; Mouridsen, HT	1
Beex, L; Biganzoli, L; Cameron, D; Cufer, T; Dirix, L; Duchateau, L; Hamilton, A; Lobelle, JP; Lohrisch, C; Nooij, M; Paridaens, R; Piccart, M	1
Brodie, AH; Jelovac, D; Long, B	1
Ellis, MJ	1
Atalay, G; Beex, L; Biganzoli, L; Cameron, D; Cufer, T; Dirix, L; Lobelle, JP; Lohrisch, C; Mattiaci, MR; Nooij, M; Paridaens, R; Piccart, M	1
Domont, J; Khayat, D; Namer, M; Spano, JP	1
Kawakami, M; Saji, S; Toi, M	1
Alvarez, I; Andersen, J; Bajetta, E; Bertelli, G; Bliss, JM; Carpentieri, M; Coates, AS; Cocconi, G; Coleman, RE; Coombes, RC; Delozier, T; Dodwell, D; Fallowfield, LJ; Gibson, LJ; Hall, E; Jassem, J; Jones, SE; Lønning, PE; Massimini, G; Mickiewicz, E; Ortmann, O; Paridaens, R; Snowdon, CF; Stewart, A; Stuart, N; van de Velde, C	1
Piccart-Gebhart, MJ	1
Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V	1
Campos, SM	1
Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D	1
Arora, A; Potter, JF	1
Clemons, M; Coleman, RE; Verma, S	1
Sainsbury, R	1
Kunkler, IH	1
De Neve, W; Vakaet, LA	1
Tanvetyanon, T	1
Aebi, S; Baumann, ChK	1
Mouridsen, HT	1
Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL	1
Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L	1
de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B	1
Fentiman, IS	1
Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE	1
Clemons, MJ; Freedman, OC; Verma, S	1
Michaud, LB	1
Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR	1
Barash, NIu; Berstein, LM; Bozhok, AA; Dashian, GA; Ivanov, VG; Klemtsel', AA; Mel'nikova, OA; Paltuev, RM; Petrovskiĭ, SG; Semiglazov, VF; Semiglazov, VV; Tonuzov, EE; Zhil'tsova, EK	1
Jakesz, R	1
Dodwell, D; Vergote, I	1
Ingle, JN; Suman, VJ	1
Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S	1
Vogel, V	1
Gogas, H; Koukouras, D; Lappas, H; Markopoulos, C; Papadiamantis, J; Polychronis, A; Xepapadakis, G; Zobolas, V	1
Pritchard, KI; Wong, NS	1
Esteva, FJ; Hortobagyi, GN	1
Abram, P; Vergote, I	1
Hutchinson, L	1
Howell, A; Locker, GY	1
Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E	1
Bliss, JM; Coombes, RC; Fallowfield, LJ; Hall, E; Jones, SE; Porter, LS; Price, MH; Snowdon, CF	1
Gltick, S	1
Come, SE	1
Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F	1
Grana, G	1
Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS	1
Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C	1
Brown, MM; Manquez, ME; Shields, CL; Shields, JA	1
Cadirni, A; Campagna, S; Francini, E; Francini, G; Gonnelli, S; Montagnani, A; Petrioli, R	1
Fricker, J	1
Dewar, R; Rayson, D; Skedgel, C; Younis, T	2
Cadirni, A; Caffarelli, C; Franci, MB; Francini, G; Gonnelli, S; Lucani, B; Montagnani, A; Nuti, R; Petrioli, R	1
Holmberg, S; Jönsson, L; Lundkvist, J; Wilking, N	1
Chu, QD; Li, BD; McDonald, JC	1
Inoue, K; Nagamoto, N; Ohsako, T; Tanaka, E; Yoshida, Y	1
Ellis, MJ; Rigden, CE	1
Bundred, NJ	1
Banks, LM; Bliss, JM; Cawthorn, SJ; Coleman, RE; Coombes, RC; Fox, J; Girgis, SI; Hall, E; Kilburn, LS; Patel, A; Snowdon, CF; Vrdoljak, E	1
Boccardo, F; Rubagotti, A	1
Alvarez, I; Andersen, J; Bajetta, E; Bertelli, G; Bliss, JM; Bogle, RG; Carpentieri, M; Castiglione, M; Coates, AS; Cocconi, G; Colajori, E; Coleman, RE; Coombes, RC; Del Mastro, L; Delozier, T; Diedrich, K; Dodwell, D; Fallowfield, LJ; Forbes, J; Hall, E; Holmberg, SB; Ireland, E; Jassem, J; Jones, SE; Kilburn, LS; Lønning, PE; Mickiewicz, E; Ortmann, O; Paridaens, R; Snowdon, CF; Stewart, A; Stuart, N; Subar, M; Van de Velde, CJ	1
Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG	1
Lian, ZQ; Yang, MT	1
Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y	1
Carlini, P; Cognetti, F; Felici, A; Ferretti, G	1
Noda, S; Toji, E; Ueda, M	1
Atkins, CD	1
Mittmann, N; Risebrough, NA; Trudeau, M; Verma, S	1
Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L	1
Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T	1
Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M	1
Fabian, CJ	1
Perez, EA	1
Jahanzeb, M	1
Asmar, L; Blum, JL; Bordelon, JH; Brooks, R; Cantrell, J; Chittoor, S; Davis, JC; Hartung, NL; Holmes, FA; Ilegbodu, D; Jones, SE; Ketchel, SJ; Kochis, J; Negron, AG; O'Shaughnessy, J; Pippen, J; Richards, DA; Rivera, R; Vukelja, S; Whittaker, TL	1
Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N	1
Bundred, NJ; Iddon, J	1
Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M	1
Cuzick, J	1
Blackwell, KL; Herold, CI	2
Burns, R; Come, SE; Farag, N	1
Castiglione-Gertsch, M; Coates, AS; Fleming, GF; Francis, P; Gelber, RD; Goldhirsch, A; Maibach, R; Pagani, O; Perez, EA; Price, KN; Regan, MM; Thürlimann, B; Torrisi, R; Walley, B	1
Atkins, JN; Costantino, JP; Eisen, A; Farrar, WB; Fehrenbacher, L; Ganz, PA; Geyer, CE; Hoehn, JL; Hutchins, LF; Ingle, JN; Jeong, JH; Kroener, JF; Land, SR; Mamounas, EP; Pajon, ER; Robidoux, A; Smith, RE; Vogel, VG; Wickerham, DL; Wolmark, N	1
Aapro, M	1
Borges, VF; Elias, AD; Finlayson, C; Harvell, DM; Horwitz, KB; Richer, JK; Singh, M; Spoelstra, N	1
Jassem, J	1
Jeong, JH	1
Pennery, E	1
Marshall, C; Thomas, R; Walker, L; Williams, M	1
Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P	1
Fields, MM; Mellington, TE	1
Gligorov, J; Nabholtz, JM	1
Nagykálnai, T	1
Dafni, U; Gogas, H; Koukouras, D; Markopoulos, C; Polychronis, A; Tzorakoleftherakis, E; Xepapadakis, G; Zobolas, V	1
Beex, LV; Boogerd, W; Eggens, PC; Gundy, CM; Linn, SC; Schagen, SB; Schilder, CM; Seynaeve, C; Van Dam, FS	1
Beex, LV; Bogaerts, J; Cameron, DA; Cufer, T; Dirix, LY; Nooij, M; Paridaens, RJ; Piccart, MJ; Therasse, P	1
Cadirni, A; Caffarelli, C; Campagna, MS; Del Santo, K; Gonnelli, S; Montagnani, A; Montomoli, M; Nuti, R; Petrioli, R; Pieropan, C	1
Asmar, L; Blum, JL; Braun, M; Cantrell, J; Davis, JC; Di Salle, E; Ethirajan, S; Hartung, NL; Holmes, FA; Ilegbodu, D; Jones, S; Kutteh, L; Look, RM; Myron, MC; Patel, M; Paul, D; Pippen, J; Sborov, M; Stokoe, C	1
Dornoff, W; Hadji, P; Hasenburg, A; Kieback, DG; Kuck, J; Melchert, F; Menschik, T; Tessen, HW; Ziller, M	1
Hadji, P; Hasenburg, A; Kalder, M; Kieback, DG; Kuck, J; Menschik, T; Ziller, M	1
Antonopoulou, Z; Dafni, U; Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Papadiamantis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V	1
Bertelli, G; Bliss, JM; Coombes, RC; Drosik, K; Hall, E; Ireland, E; Jassem, J; Karnicka-Mlodkowska, H; Snowdon, CF	1
Glück, S	1
Lazarus, P; Sun, D	1
Auboeuf, D; Bénès, V; Dalenc, F; Gratadou, L; Lacroix-Triki, M; Maillot, G; Millevoi, S; Pierredon, S; Roché, H; Schmidt, S; Vagner, S	1
Beex, LV; de Jong, RS; Maartense, E; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Roumen, RM; Seynaeve, C; van de Velde, CJ; van Nes, JG	1
Chen, S; Masri, S; Phung, S; Wang, X	1
Aogi, K; Hara, F; Kiyoto, S; Osumi, S; Takabatake, D; Takashima, S	1
Beex, LV; Boogerd, W; Gundy, CM; Linn, SC; Nortier, JW; Schagen, SB; Schilder, CM; Seynaeve, C; van Dam, FS; van de Velde, CJ	2
Beex, LV; Boogerd, W; Gundy, CM; Huizenga, HM; Linn, SC; Nortier, JW; Schagen, SB; Schilder, CM; Seynaeve, C; van Dam, FS; van de Velde, CJ	1
Dirix, L; Hasenburg, A; Hille, ET; Hozumi, Y; Jones, S; Kerin, MJ; Kieback, DG; Markopoulos, C; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Rea, DW; Seynaeve, C; van de Velde, CJ; van Nes, JG; Vannetzel, JM	1
Cartei, G; Endri, M; Fassina, A; Serino, FS; Zustovich, F	1
Rabaglio, M; Ruepp, B	1
A'Hern, R; Charles, P; Flockhart, DA; Hayes, DF; Henry, NL; Li, L; Nguyen, AT; Pchejetski, D; Stearns, V; Stebbing, J; Storniolo, AM; Waxman, J	1
Agrawal, K; Mortimer, JE; Onami, S; Pal, SK	1
Banks, LM; Bliss, JM; Cawthorn, SJ; Coleman, RE; Coombes, RC; Fox, J; Girgis, SI; Kilburn, LS; Patel, A; Vrdoljak, E	1
Bauer, W; Hadji, P; Harbeck, N; Hasenburg, A; Kieback, DG; Menschik, T; Weyer, G	1
Agrawal, A; Cheung, KL; Dowsett, M; Folkerd, E; Robertson, JF; Winterbottom, L	1
Tang, SC	1
Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S	1
Asmar, L; Hadji, P; Hasenburg, A; Jones, SE; Kuck, J; Menschik, T; Nortier, JW; van de Velde, CJ; van Nes, JG; Ziller, M	1
Asmar, L; Bartlett, JM; Hadji, P; Hasenburg, A; Hille, ET; Hozumi, Y; Jones, SE; Kieback, DG; Markopoulos, C; Nortier, JW; Paridaens, R; Putter, H; Rea, D; Seynaeve, C; Smeets, J; van de Velde, CJ; Vannetzel, JM	1
Coombes, RC; Kilburn, LS	1
Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H	1
Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H	2
Doughty, JC	1
Bartlett, JM; Billingham, LJ; Brookes, CL; Campbell, FM; Dirix, L; Grant, M; Hasenburg, A; Hille, ET; Kay, C; Kieback, DG; Kranenbarg, EM; Mallon, EA; Markopoulos, C; Putter, H; Rea, D; Robson, T; Seynaeve, C; van de Velde, CJ	1
Aogi, K; Hara, F; Kiyoto, S; Ohsumi, S; Takabatake, D; Takahashi, M; Takashima, S	1
Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H	1
Ma, CX	1
Bartlett, AI; Bartlett, JM; Campbell, FM; Hasenburg, A; Maclellan, A; Markopoulos, C; Rea, D; Robson, T; Seynaeve, C; Starcyznski, J; van de Velde, CJ	1
Alba Conejo, E; Bayo Calero, J; de la Cabeza Lomas Garrido, M; de la Haba Rodríguez, J; de Toro Salas, R; González Mancha, R; Martínez Guisado, A; Ruíz Borrego, M; Sánchez Muñoz, A	1
Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E	1
Schmidt, C	1
Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K	1
Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL	1
Bell, LN; Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Wolff, AC	1
Bastiaannet, E; de Craen, AJ; Hille, ET; Liefers, GJ; Meershoek-Klein Kranenbarg, EM; Paridaens, R; Putter, H; Seynaeve, CM; van de Velde, CJ; van de Water, W; Westendorp, RG	1
Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H	1
Goss, PE; Liedke, PE	1
Bliss, JM; Coombes, RC; Mieog, JS; Morden, JP; van de Velde, CJ	1
Burstein, HJ; Griggs, JJ	1
Gabriel, EM; Jatoi, I	1
Bastiaannet, E; de Craen, AJ; Hadji, P; Hasenburg, A; Hille, ET; Jones, SE; Liefers, GJ; Markopoulos, C; Nortier, JW; Putter, H; Rea, D; Seynaeve, C; van de Velde, CJ; van de Water, W; Westendorp, RG	1
Bauer, T; Hadji, P; Hasenburg, A; Kauka, A; Kieback, DG; Tams, J	1
Bliss, JM; Coombes, RC; Fallowfield, LJ; Kilburn, LS; Langridge, C; Snowdon, CF	1
de Haes, JC; Fontein, DB; Hille, ET; Nortier, JW; Putter, H; Seynaeve, C; van de Velde, CJ; van Leeuwen, FE; van Nes, JG; Voskuil, DW	1
Hadji, P; Hasenburg, A; Kieback, DG; Tams, J; Ziller, M	1
Kolesar, JM; Simondsen, K; Zhang, Y	1
Bartlett, JM; Dirix, LY; Fontein, DB; Hille, ET; Kranenbarg, EM; Liefers, GJ; Nortier, JW; Paridaens, R; Putter, H; Robson, T; Roumen, RM; Seynaeve, C; van de Velde, CJ; van de Water, W; van Nes, JG	1
Becker, M; Bossart, M; Hadji, P; Hasenburg, A; Kieback, DG	1
Bartlett, JM; Beck, RA; Bloom, KJ; Dirix, L; Hasenburg, A; Kieback, D; Lawton, TJ; Markopoulos, C; Piper, T; Putter, H; Rea, D; Ring, BZ; Ross, DT; Seitz, RS; Seynaeve, C; van de Velde, CJ	1
Bhargava, R; Brufsky, AM; Davidson, NE	1
Climent, MA; Folkerd, E; García, A; Gavilá, J; Guerrero, A; Guillem, V; Martínez, F; Ortiz, B; Ruíz, A	1
Belli, AK; Buckley, JM; Coopey, SB; Gadd, MA; Garber, JE; Guidi, AJ; Hughes, KS; Kim, EM; Mazzola, E; Parmigiani, G; Polubriaginof, F; Roche, CA; Sharko, J; Smith, BL; Specht, MC	1
Bastiaannet, E; de Craen, AJ; Hasenburg, A; Hille, ET; Jones, SE; Liefers, GJ; Markopoulos, C; Paridaens, R; Putter, H; Rea, D; Seynaeve, C; van de Velde, CJ; van de Water, W; Westendorp, RG	1
Tung, N	1
Bartlett, JM; Fontein, DB; Hadji, P; Hasenburg, A; Hille, ET; Hozumi, Y; Jones, SE; Kranenbarg, EM; Markopoulos, C; Nortier, JW; Paridaens, RJ; Putter, H; Rea, DW; Seynaeve, C; van de Velde, CJ; van de Water, W; Vannetzel, JM	1
Henry, NL; Stearns, V	1
Brauch, H; Precht, JC; Saladores, PH; Schroth, W; Schwab, M	1
Bastiaannet, E; Hasenburg, A; Hozumi, Y; Jones, SE; Liefers, GJ; Marijnen, CA; Markopoulos, C; Paridaens, R; Putter, H; Rea, D; Scholten, AN; Seynaeve, C; van de Velde, CJ; van Hezewijk, M	1
Bartlett, JM; Brookes, CL; Dirix, LY; Hasenburg, A; Kieback, DG; Kranenbarg, EM; Lyttle, N; Mallon, EA; Markopoulos, C; Piper, T; Putter, H; Quintayo, MA; Rea, DW; Seynaeve, C; Stocken, D; van de Velde, CJ	1
Coates, AS; Colleoni, M; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Maibach, R; Pagani, O; Price, KN; Rabaglio, M; Regan, MM; Ruepp, B; Walley, BA	1
Mehta, A; Tripathy, D	1
Bossart, M; Hadji, P; Hasenburg, A; Kieback, DG; Klar, M	1
Harris, LN; Williams, N	1
Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M	1
A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE	1
Chlebowski, RT	1
Bastiaannet, E; de Craen, AJ; Kiderlen, M; Liefers, GJ; Nortier, JW; Seynaeve, C; Siesling, S; van de Velde, CJ; van de Water, W; Westendorp, RG	1
Bastiaannet, E; De Craen, AJ; de Glas, NA; de Haes, HJ; Fontein, DB; Liefers, GJ; Nortier, HJ; Pijpe, A; van de Velde, CJ; van Leeuwen, FE	1
Bernhard, J; Bonnefoi, HR; Burstein, HJ; Ciruelos, E; Coates, AS; Colleoni, M; Crivellari, D; Fleming, GF; Francis, PA; Gelber, RD; Geyer, CE; Giobbie-Hurder, A; Goldhirsch, A; Gomez, HL; Láng, I; Luo, W; Maibach, R; Martino, S; Pagani, O; Perez, EA; Pinotti, G; Price, KN; Puglisi, F; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Ruepp, B; Ruhstaller, T; Stearns, V; Tondini, C; Viale, G; Walley, BA; Winer, EP	1
Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W	1
Rugo, HS	1
Bartlett, JM; Brookes, CL; Crozier, C; Dirix, L; Drake, C; Hasenburg, A; Kieback, DG; Markopoulos, C; Piper, T; Rea, DW; Sabine, VS; Seynaeve, C; van de Velde, CJ	1
Yaqub, F	1
Printz, C	1
Albertini, S; Kelly, E; Lu, CY; Vitry, A	1
Beex, LV; Duijm-de Carpentier, M; Lardenoije, S; Nortier, JW; Putter, H; Seynaeve, C; Sramek, A; van de Velde, CJ; van Nes, JG; Van Rongen, I; Zonderland, HM	1
Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I	1
Bellet, M; Bonnefoi, HR; Buchholz, S; Burstein, HJ; Ciruelos, E; Climent, MA; Coates, AS; Coleman, R; Colleoni, M; Da Prada, GA; Davidson, NE; Fleming, GF; Francis, PA; Gelber, RD; Geyer, CE; Giobbie-Hurder, A; Goldhirsch, A; Ingle, JN; Kerbrat, P; Láng, I; Maibach, R; Martino, S; Price, KN; Rabaglio-Poretti, M; Regan, MM; Ruepp, B; Viale, G; Walley, BA; Winer, EP	1
Hershman, DL	1
Ch Yiannakopoulou, E	1
Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P	1
Liu, J; Zhu, L	1
Bartlett, JM; Bastiaannet, E; Charehbili, A; Engels, CC; Kuppen, PJ; Liefers, GJ; Putter, H; Sajet, A; Seynaeve, C; Smit, VT; van de Velde, CJ; van Vlierberghe, RL; van Vliet, EA	1
Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW	1
Piccart, M; Sonnenblick, A	1
Diener-West, M; Prasad, V	1
Bevers, TB	1
Chang, CH; Chen, SJ; Liu, CY	1
Bartlett, JMS; Bliss, JM; Cheang, M; Coombes, RC; Jassem, J; Kalaitzaki, E; Lønning, PE; Mousa, K; Nicholas, H; Palmieri, C; Rasmussen, BB; Reed, SN; Shaaban, AM; Speirs, V; van de Velde, CJH; Verhoeven, DM; Viale, G	1
Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E	1
de la Vega, M; Díaz Cantón, E; Greco, M; Recondo, G; Valsecchi, ME	1
Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I	1
Cottu, P; Donnadieu, A; Leman-Detours, S; Saltel-Fulero, A	1
Bartlett, JM; Christiansen, J; Dirix, LY; Gustavson, M; Hasenburg, A; Kieback, DG; Markopoulos, CJ; Piper, T; Putter, H; Rea, DW; Rimm, DL; Seynaeve, C; van de Velde, CJ	1
Avella, A; Azaro, A; Bellet, M; Bohn, U; Catalán, G; Catalán, R; Ciruelos, E; Climent, MA; Ferrer, R; Fleming, GF; Francis, PA; González-Martin, A; Gray, KP; Láng, I; Lluch, A; Morales, J; Price, KN; Rajasekaran, A; Regan, MM; Vázquez, J	1
Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P	1
Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M	1
DeCensi, A; Lazzeroni, M	1
Amaral, C; Correia-da-Silva, G; Sobral, AF; Teixeira, N	1
Bellet, M; Bernhard, J; Burstein, HJ; Ciruelos, E; Coates, AS; Colleoni, M; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Karlsson, P; Kerbrat, P; Lluch, A; Lombardi, D; Luo, W; Neven, P; Parmar, V; Pavesi, L; Perelló, A; Price, KN; Puglisi, F; Regan, MM; Ribi, K; Ruhstaller, T; Tondini, C; Torres, R; Visini, M	1
Coates, AS; Colleoni, M; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Gómez, HL; Láng, I; Pagani, O; Pinotti, G; Price, KN; Regan, MM; Tondini, C; Viale, G; Walley, BA	1
Henry, NL; Kadakia, KC	1
Francis, PA; Pagani, O; Regan, MM	1
Chen, WG; Chen, XS; Fang, Q; He, JR; Huang, O; Li, YF; Liang, Y; Nie, LJ; Shen, KW; Wu, JY; Zhu, L; Zong, Y	1
Gilarranz, YJ; Lopez-Tarruella, S; Martin, M	1
Altinok, AY; Altug, T; Azria, D; Bese, NS; Ober, A; Ozsahin, EM; Sut, N; Yildirim, S	1
Arellano, C; Chatelut, E; Dalenc, F; Filleron, T; Iuliano, L; Marquet, P; Poirot, M; Roché, H; Samadi, M; Silvente-Poirot, S; Voisin, M; Zerbinati, C	1
Burns, RB; Libman, H; Schonberg, MA; Tung, NM	1
Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D	1
Giorgadze, E; Khachidze, N; Tsagareli, M	1
Cohen, PR	1
Caramia, F; Joshi, S; Loi, S; Moodie, K; Savas, P; Van Geelen, C; Wein, L	1
Alvarez, I; Andersen, J; Bertelli, G; Bliss, JM; Coates, AS; Coleman, R; Coombes, RC; Del Mastro, L; Dodwell, D; Fallowfield, L; Holmberg, S; Jassem, J; Jones, S; Kilburn, L; Lønning, PE; Morden, JP; Nicholas, H; Ortmann, O; Paridaens, R; Snowdon, C; van de Velde, C	1
Bellet, M; Bernhard, J; Burstein, HJ; Coates, AS; Colleoni, M; Dane, F; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Gómez, HL; Luo, W; Moreira, A; Nottage, M; Pagani, O; Parmar, V; Perelló, A; Price, KN; Regan, MM; Ribi, K; Saha, P; Stewart, J; Torres, R; Vorobiof, D; Walley, BA	1
Gemignani, ML; Hetzel, DJ	1
Francis, PA	2
Martin, M	1
Blok, EJ; Derks, MGM; Dirix, LY; Hasenburg, A; Kranenbarg, EM; Kroep, JR; Liefers, GJ; Markopoulos, C; Nortier, JWR; Paridaens, R; Putter, H; Rea, D; Seynaeve, C; Smeets, JBE; van de Velde, CJH	1
He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S	1
Bartlett, JMS; Bliss, JM; Cheang, MCU; Coombes, RC; Jassem, J; Lønning, PE; Morden, J; Palmieri, C; Porta, N; Rasmussen, BB; Shaaban, A; Speirs, V; van De Velde, CJ; Verhoeven, D; Viale, G	1
Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C	1
Dirix, LY	1
Alunni-Fabbroni, M; Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TWP; Gade, J; Janni, W; Lichtenegger, W; Lorenz, R; Mahner, S; Müller, V; Pantel, K; Polasik, A; Rack, B; Rezai, M; Schindlbeck, C; Schneeweiss, A; Schochter, F; Soeling, U; Tesch, H; Trapp, E; Tzschaschel, M	1
Evans, DG; Howell, A; Howell, SJ	1
Bellet, M; Bonnefoi, HR; Buchholz, S; Burstein, HJ; Ciruelos, E; Climent, MA; Coates, AS; Coleman, R; Colleoni, M; Davidson, NE; Debled, M; Di Leo, A; Fleming, GF; Francis, PA; Gelber, RD; Geyer, CE; Goetz, MP; Goldhirsch, A; Gómez, HL; Ingle, JN; Láng, I; Maibach, R; Martino, S; Pagani, O; Pavesi, L; Pinotti, G; Puglisi, F; Rabaglio-Poretti, M; Regan, MM; Ruepp, B; Ruhstaller, T; Spazzapan, S; Stearns, V; Tondini, C; Walley, BA; Winer, EP	1
Bastiaannet, E; de Glas, NA; Derks, MGM; Dirix, LY; Hasenburg, A; Liefers, GJ; Markopoulos, C; Nortier, JWR; Portielje, JEA; Putter, H; Rea, D; Seynaeve, C; van de Velde, CJH; van de Water, W	1
Bartlett, JMS; Bayani, J; Bennett, L; Cheng, K; Dickson, A; Dirix, LY; Edwards, J; Hasenburg, A; Horgan, PG; Kieback, DG; Mallon, EA; Markopoulos, C; McMillan, DC; Quintayo, MA; Rea, DW; Roseweir, AK; Seynaeve, C; van de Velde, CJH	1
O'Shaughnessy, J; Royce, M; Thaddeus Beck, J	1
Chang, B; Fan, X; Jiang, X; Kariminia, S; Li, L; Li, Q; Li, T; Li, Y; Wu, S; Zhang, J	1
Beijnen, JH; de Jong, KAM; de Vries, N; Rosing, H; van Nuland, M; Venekamp, N	1
Ali, S; Bliss, JM; Cheang, MCU; Coombes, RC; Flach, KD; Linn, SC; Opdam, M; Palmieri, C; Szijgyarto, Z; Wesseling, J; Zwart, W	1
Clark, BL; Gersch, CL; Gregory, BJ; Hayes, DF; Henry, NL; Hertz, DL; Kamdem, LK; Kidwell, KM; Rae, JM; Stearns, V; Storniolo, AM; Xi, J	1
Dempsey, JM; Desta, Z; Gersch, CL; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Pesch, AM; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM	1
Chen, W; Lin, X; Wei, F	1
Alviggi, C; Arpino, G; Caputo, R; Conforti, A; De Laurentiis, M; De Placido, G; De Placido, S; De Rosa, P; De Santo, I; Di Rella, F; Giuliano, M; Lauria, R; Locci, M; Nazzaro, G; Schettini, F; Vallone, R	1
DiNardo, D; Farkas, A; Merriam, S; Vanderberg, R	1
Coates, AS; Colleoni, M; Di Leo, A; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Gómez, HL; Láng, I; Pagani, O; Pinotti, G; Regan, MM; Tondini, C; Viale, G; Walley, BA	1
Chen, J; Fan, Y; He, T; Huang, Q; Li, P; Lv, Q; Wu, Y; Xiang, M; Yang, D; Yang, W; Zhang, X; Zhou, R	1
Petit, T	1
Amaral, C; Fernandes, PA; Ferreira Almeida, C; João Ramos, M; Oliveira, A; Teixeira, N	1
Ingle, JN; Qin, S; Wang, L; Yu, J; Zayas, J	1
DiNome, ML; Ganz, PA; Graham, D	1
Bartlett, JMS; Blok, EJ; Duijm-de Carpentier, M; Hasenburg, A; Hozumi, Y; Kroep, JR; Liefers, GJ; Markopoulos, CJ; Meershoek-Klein Kranenbarg, E; Noordhoek, I; Paridaens, R; Portielje, JEA; Putter, H; Rea, DW; Rutgers, EJT; Seynaeve, C; van de Velde, CJH; Vannetzel, JM	1
Ahn, HK; Im, SA; Jung, KH; Kang, SY; Kim, GM; Kim, JH; Lee, J; Park, IH; Park, YH	1
Chan, RJ; Fardell, JE; Vardy, JL; Walker, A	1
Boogerd, W; Kieffer, JM; Lee Meeuw Kjoe, PR; Meershoek-Klein Kranenbarg, E; Schagen, SB; Schilder, CM; Small, BJ; van de Velde, CJH; van der Wall, E	1

Reviews

83 review(s) available for aromasil and tamoxifen

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Use of aromatase inhibitors in breast carcinoma. Endocrine-related cancer, 1999, Volume: 6, Issue:1 Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles	1999
Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:5 Suppl 7 Topics: Androstadienes; Breast Neoplasms; Female; Humans; Meta-Analysis as Topic; Tamoxifen; Time Factors	2001
Role of anti-aromatase agents in postmenopausal advanced breast cancer. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:4 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles	2001
Third-generation aromatase inhibitors in the treatment of advanced breast cancer. Breast cancer (Tokyo, Japan), 2001, Volume: 8, Issue:4 Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles	2001
A summary of second-line randomized studies of aromatase inhibitors. The Journal of steroid biochemistry and molecular biology, 2001, Volume: 79, Issue:1-5 Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles	2001
Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Suppl Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles	2001
Antiaromatase agents: evolving role in adjuvant therapy. Clinical breast cancer, 2002, Volume: 3, Issue:1 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles	2002
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile]. Minerva ginecologica, 2002, Volume: 54, Issue:2 Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles	2002
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. American journal of clinical oncology, 2003, Volume: 26, Issue:4 Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles	2003
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. American journal of clinical oncology, 2003, Volume: 26, Issue:4 Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays	2003
[Neoadjuvant endocrine therapy for breast cancer: an overview]. Bulletin du cancer, 2004, Volume: 91, Issue:1 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles	2004
[Controversies in endocrine therapy for breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles	2004
Aromatase inhibitors for breast cancer in postmenopausal women. The oncologist, 2004, Volume: 9, Issue:2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles	2004
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:4 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration	2004
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer treatment reviews, 2004, Volume: 30, Issue:4 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles	2004
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? British journal of cancer, 2004, May-04, Volume: 90, Issue:9 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles	2004
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas]. Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:6 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles	2004
Current developments in hormonal therapy of breast cancer. Clinical breast cancer, 2004, Volume: 5 Suppl 1 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles	2004
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer, 2004, Oct-01, Volume: 101, Issue:7 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles	2004
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]. Bulletin du cancer, 2004, Volume: 91, Issue:12 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2004
Aromatase inhibitors and breast cancer: time for a change? International journal of clinical practice, 2004, Volume: 58, Issue:12 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles	2004
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles	2005
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer treatment reviews, 2005, Volume: 31, Issue:1 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles	2005
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, Feb-01, Volume: 62, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles	2005
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer treatment reviews, 2005, Volume: 31, Issue:4 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles	2005
Aromatase inhibitors for therapy of advanced breast cancer. The Journal of steroid biochemistry and molecular biology, 2005, Volume: 95, Issue:1-5 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles	2005
Chemoprevention in breast cancer. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:7 Topics: Age Factors; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Female; Humans; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen	2005
A review of exemestane in the management of breast cancer. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:13 Topics: Administration, Oral; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Megestrol Acetate; Multicenter Studies as Topic; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome	2005
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides	2006
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles	2006
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer. Clinical breast cancer, 2005, Volume: 6, Issue:4 Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Nitriles; Research Design; Tamoxifen; Triazoles	2005
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data. Journal of surgical oncology, 2006, Jun-01, Volume: 93, Issue:7 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles	2006
Adjuvant therapy for patients who have node-positive breast cancer. Advances in surgery, 2006, Volume: 40 Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles	2006
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data. Current medical research and opinion, 2006, Volume: 22, Issue:12 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles	2006
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole]. Nederlands tijdschrift voor geneeskunde, 2006, Dec-30, Volume: 150, Issue:52 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles	2006
[Advancement in endocrine therapy for breast cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2007
Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health technology assessment (Winchester, England), 2007, Volume: 11, Issue:26 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles	2007
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer]. Ugeskrift for laeger, 2007, Sep-10, Volume: 169, Issue:37 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles	2007
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. International journal of clinical practice, 2007, Volume: 61, Issue:12 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles	2007
Safety of aromatase inhibitors in the adjuvant setting. Breast cancer research and treatment, 2007, Volume: 105 Suppl 1 Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles	2007
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Clinical therapeutics, 2007, Volume: 29, Issue:8 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles	2007
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision? Expert review of anticancer therapy, 2008, Volume: 8, Issue:1 Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Selective Estrogen Receptor Modulators; Tamoxifen	2008
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer treatment reviews, 2008, Volume: 34, Issue:2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles	2008
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. Breast (Edinburgh, Scotland), 2008, Volume: 17 Suppl 1 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles	2008
Statistical analysis in cancer clinical trials. Anti-cancer drugs, 2008, Volume: 19 Suppl 1 Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen	2008
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2008, Volume: 12, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles	2008
Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anti-cancer drugs, 2008, Volume: 19, Issue:4 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles	2008
Targeting breast cancer with hormonal treatment options. The Nurse practitioner, 2008, Volume: 33, Issue:5 Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles	2008
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. Reviews on recent clinical trials, 2006, Volume: 1, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles	2006
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. Clinical breast cancer, 2008, Volume: 8, Issue:1 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles	2008
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?]. Magyar onkologia, 2008, Volume: 52, Issue:2 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles	2008
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. American journal of clinical oncology, 2010, Volume: 33, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles	2010
Women and bone health: maximizing the benefits of aromatase inhibitor therapy. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid	2010
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:6 Topics: Androstadienes; Antineoplastic Agents; Belgium; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Germany; Hip; Humans; Lumbar Vertebrae; Middle Aged; Netherlands; Randomized Controlled Trials as Topic; Tamoxifen; United States	2011
When to start an aromatase inhibitor: now or later? Journal of surgical oncology, 2011, Jun-01, Volume: 103, Issue:7 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2011
Overview of adjuvant trials of aromatase inhibitors in early breast cancer. Steroids, 2011, Volume: 76, Issue:8 Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles	2011
Preventive therapy for breast cancer: a consensus statement. The Lancet. Oncology, 2011, Volume: 12, Issue:5 Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles	2011
Initialization of adjuvant hormonal treatment for breast cancer. Advances in therapy, 2011, Volume: 28 Suppl 6 Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Detection of Cancer; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles	2011
Breast cancer chemoprevention. Expert review of anticancer therapy, 2012, Volume: 12, Issue:2 Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen	2012
Pharmacogenomics of endocrine therapy in breast cancer. Journal of human genetics, 2013, Volume: 58, Issue:6 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2013
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. Expert review of molecular diagnostics, 2013, Volume: 13, Issue:4 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Pharmacological; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Humans; Letrozole; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles	2013
Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles	2014
The renaissance of endocrine therapy in breast cancer. Current opinion in obstetrics & gynecology, 2014, Volume: 26, Issue:1 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Ovariectomy; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome	2014
Current concepts in breast cancer chemoprevention. Polskie Archiwum Medycyny Wewnetrznej, 2014, Volume: 124, Issue:4 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles	2014
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review. American journal of clinical oncology, 2015, Volume: 38, Issue:6 Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; Drug Synergism; Female; Humans; Salicylates; Tamoxifen	2015
Adjuvant systemic therapy in breast cancer: quo vadis? Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8 Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms	2015
Anti-Hormonal Therapies for Premenopausal Patients--What did we Learn from the TEXT/SOFT Trials? Reviews on recent clinical trials, 2015, Volume: 10, Issue:2 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Multicenter Studies as Topic; Ovary; Premenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triptorelin Pamoate	2015
[New options in adjuvant endocrine therapy in breast cancer]. Bulletin du cancer, 2016, Volume: 103, Issue:1 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Antagonists; Estrogens; Female; Humans; Menopause; Receptors, Estrogen; Tamoxifen; Time Factors	2016
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?]. Bulletin du cancer, 2016, Volume: 103, Issue:3 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles	2016
Alternate dosing schedules for cancer chemopreventive agents. Seminars in oncology, 2016, Volume: 43, Issue:1 Topics: Administration, Oral; Androstadienes; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemoprevention; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ki-67 Antigen; Preoperative Care; Risk Factors; Tamoxifen	2016
Unravelling exemestane: From biology to clinical prospects. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 163 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biotransformation; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Tamoxifen; Triazoles	2016
Endocrine therapy for hormone treatment-naïve advanced breast cancer. Breast (Edinburgh, Scotland), 2016, Volume: 28 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles	2016
Endocrine treatment in breast cancer: Cure, resistance and beyond. Cancer treatment reviews, 2016, Volume: 50 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyridines; Receptors, Estrogen; Tamoxifen	2016
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE). Georgian medical news, 2017, Issue:262 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2017
Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer. Gynecologic oncology, 2017, Volume: 147, Issue:1 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen	2017
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. Medicine, 2017, Volume: 96, Issue:33 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles	2017
Personalized prevention in high risk individuals: Managing hormones and beyond. Breast (Edinburgh, Scotland), 2018, Volume: 39 Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles	2018
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer. Cancer treatment reviews, 2018, Volume: 69 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Tamoxifen	2018
Efficacy and safety of adjuvant endocrine therapy in premenopausal patients with early-stage hormone receptor-positive breast cancer: A meta-analysis of randomized controlled trials. The breast journal, 2019, Volume: 25, Issue:6 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Glucose Intolerance; Humans; Neoplasm Staging; Pharmacovigilance; Premenopause; Receptors, Estrogen; Tamoxifen; Treatment Outcome	2019
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. Medicine, 2020, Volume: 99, Issue:2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Letrozole; Lipids; Network Meta-Analysis; Research Design; Tamoxifen; Toremifene	2020
[Endocrine adjuvant treatment specific features for young breast cancer women]. Bulletin du cancer, 2019, Volume: 106, Issue:12S1 Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Luteolytic Agents; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triptorelin Pamoate	2019
Estrogen receptor-positive (ER Biochemical pharmacology, 2020, Volume: 177 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Fulvestrant; Gene Expression; Humans; Molecular Targeted Therapy; Tamoxifen	2020

Trials

78 trial(s) available for aromasil and tamoxifen

Article	Year
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:7 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Pain; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Treatment Outcome	2000
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Tamoxifen; Treatment Failure	2000
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36 Suppl 4 Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Postmenopause; Survival Analysis; Tamoxifen; Treatment Failure	2000
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clinical breast cancer, 2000, Volume: 1 Suppl 1 Topics: Administration, Oral; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Tamoxifen; Treatment Outcome	2000
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Tamoxifen; Treatment Outcome	2003
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamo Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arteriosclerosis; Breast Neoplasms; Cholesterol; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Neoplasm Metastasis; Postmenopause; Risk Factors; Tamoxifen	2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. The New England journal of medicine, 2004, Mar-11, Volume: 350, Issue:11 Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen	2004
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-15, Volume: 10, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrone; Female; History, 18th Century; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Tamoxifen	2004
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer, 2004, Oct-01, Volume: 101, Issue:7 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles	2004
Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-15, Volume: 11, Issue:4 Topics: Adult; Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, HDL; Estradiol; Estrogen Antagonists; Estrone; Exanthema; Female; Hot Flashes; Humans; Middle Aged; Postmenopause; Tamoxifen; Treatment Outcome	2005
The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast cancer research and treatment, 2005, Volume: 93, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Greece; Humans; Lipids; Middle Aged; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triglycerides	2005
Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-15, Volume: 11, Issue:24 Pt 1 Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Estradiol; Estrone; Female; Humans; Middle Aged; Postmenopause; Tamoxifen	2005
Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clinical breast cancer, 2006, Volume: 6 Suppl 2 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Disease-Free Survival; Female; Humans; Middle Aged; Postmenopause; Tamoxifen; Treatment Outcome	2006
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. British journal of cancer, 2006, Jul-17, Volume: 95, Issue:2 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Disease-Free Survival; Female; Humans; Lipid Metabolism; Middle Aged; Obesity; Postmenopause; Quality of Life; Tamoxifen; Treatment Outcome; Triglycerides	2006
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone, 2007, Volume: 40, Issue:1 Topics: Alkaline Phosphatase; Androstadienes; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Female; Humans; Middle Aged; Peptides; Radiography; Tamoxifen	2007
Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast cancer research and treatment, 2007, Volume: 102, Issue:3 Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Quality of Life; Sweden; Tamoxifen	2007
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. The Lancet. Oncology, 2007, Volume: 8, Issue:2 Topics: Androstadienes; Antineoplastic Agents; Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Follow-Up Studies; Fractures, Bone; Hip; Humans; Incidence; Lumbar Vertebrae; Postmenopause; Radiography; Risk Factors; Spine; Tamoxifen; Time Factors; Treatment Outcome	2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (London, England), 2007, Feb-17, Volume: 369, Issue:9561 Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen	2007
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast cancer research : BCR, 2007, Volume: 9, Issue:4 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles	2007
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Follow-Up Studies; Hot Flashes; Humans; Menopause; Middle Aged; Quality of Life; Surveys and Questionnaires; Tamoxifen; Time Factors; Treatment Outcome	2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5 Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen	2008
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12 Topics: Administration, Oral; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome	2008
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women. British journal of cancer, 2008, May-06, Volume: 98, Issue:9 Topics: Affect; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Patient Participation; Patient Selection; Postmenopause; Prospective Studies; Quality of Life; Research Design; Sample Size; Surveys and Questionnaires; Tamoxifen; Triazoles	2008
Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:1 Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Female; Greece; Humans; Lipid Metabolism; Lipids; Postmenopause; Tamoxifen	2009
Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:1 Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Cross-Sectional Studies; Cyclophosphamide; Depression; Doxorubicin; Fatigue; Female; Humans; Middle Aged; Postmenopause; Prospective Studies; Quality of Life; Tamoxifen	2009
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Lymphatic Metastasis; Middle Aged; Postmenopause; Soft Tissue Neoplasms; Tamoxifen; Treatment Outcome	2008
The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. European journal of internal medicine, 2008, Volume: 19, Issue:8 Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Body Composition; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Estrogen Receptor Modulators; Female; Humans; Lipids; Middle Aged; Postmenopause; Single-Blind Method; Tamoxifen; Treatment Outcome; Triglycerides	2008
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clinical breast cancer, 2008, Volume: 8, Issue:6 Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Tamoxifen	2008
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome	2009
The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast (Edinburgh, Scotland), 2009, Volume: 18, Issue:3 Topics: Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Collagen Type I; Female; Follow-Up Studies; Humans; Middle Aged; Osteocalcin; Peptides; Tamoxifen; Time Factors; Treatment Outcome	2009
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast cancer research : BCR, 2009, Volume: 11, Issue:3 Topics: Adult; Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Postmenopause; Steroids; Tamoxifen	2009
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; International Agencies; Middle Aged; Postmenopause; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Ultrasonography	2010
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer research, 2009, Nov-01, Volume: 69, Issue:21 Topics: Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Estrogen Antagonists; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Treatment Outcome	2009
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5 Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; International Agencies; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome	2010
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast cancer research and treatment, 2010, Volume: 124, Issue:1 Topics: Absorptiometry, Photon; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Australia; Biomarkers; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Estrogen Antagonists; Europe; Female; Fractures, Bone; Humans; Middle Aged; Odds Ratio; Risk Assessment; Risk Factors; Tamoxifen; Time Factors; United States	2010
Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. Gynecologic oncology, 2010, Volume: 119, Issue:3 Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Middle Aged; Postmenopause; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Ultrasonography; Uterine Diseases	2010
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet (London, England), 2011, Jan-22, Volume: 377, Issue:9762 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Early Diagnosis; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen	2011
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles; Triglycerides	2011
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Apr-20, Volume: 29, Issue:12 Topics: Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Europe; Female; Humans; Immunohistochemistry; Middle Aged; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Time Factors; Tissue Array Analysis; Treatment Outcome	2011
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. Oncology, 2010, Volume: 79, Issue:5-6 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Resorption; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles	2010
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies. Genetic epidemiology, 2012, Volume: 36, Issue:1 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles	2012
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. Journal of clinical pharmacology, 2012, Volume: 52, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Lipids; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles	2012
Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. The oncologist, 2012, Volume: 17, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Survival Rate; Tamoxifen; Treatment Outcome	2012
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N- Breast cancer research and treatment, 2012, Volume: 133, Issue:1 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Depression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles	2012
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. The Lancet. Oncology, 2012, Volume: 13, Issue:4 Topics: Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Disease-Free Survival; Female; Humans; Middle Aged; Musculoskeletal Abnormalities; Postmenopause; Retrospective Studies; Surveys and Questionnaires; Tamoxifen; Treatment Outcome	2012
Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:5 Topics: Aged; Androstadienes; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Female; Follicle Stimulating Hormone; Germany; Hormones; Humans; Middle Aged; Parathyroid Hormone; Postmenopause; Receptors, Estrogen; Sex Hormone-Binding Globulin; Tamoxifen; Testosterone	2012
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6 Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Substitution; Female; Follow-Up Studies; Humans; Libido; Neoplasms, Unknown Primary; Postmenopause; Quality of Life; Receptors, Estrogen; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Vaginal Discharge	2012
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast cancer research and treatment, 2012, Volume: 134, Issue:1 Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Postmenopause; Quality of Life; Surveys and Questionnaires; Tamoxifen	2012
Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:10 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Female; Germany; Humans; Middle Aged; Retrospective Studies; Tamoxifen	2012
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:2 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Postmenopause; Receptors, Estrogen; Tamoxifen	2013
Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial. Anticancer research, 2012, Volume: 32, Issue:9 Topics: Analgesics; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Interactions; Female; Fractures, Bone; Humans; Medication Adherence; Middle Aged; Retrospective Studies; Tamoxifen	2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Dec-20, Volume: 30, Issue:36 Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Neoplasms, Hormone-Dependent; Recurrence; Retrospective Studies; Risk Factors; Tamoxifen; Tissue Array Analysis	2012
Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis. The oncologist, 2013, Volume: 18, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Postmenopause; Recurrence; Tamoxifen; Treatment Outcome	2013
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013, Volume: 108, Issue:2 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; International Cooperation; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome	2013
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. British journal of cancer, 2013, Oct-29, Volume: 109, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Middle Aged; Molecular Sequence Data; Prognosis; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Tissue Array Analysis	2013
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:6 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ovariectomy; Ovary; Premenopause; Research Design; Statistics as Topic; Tamoxifen; Triptorelin Pamoate	2013
Effect of prior chemotherapy regimens on the efficacy of endocrine therapy within a German cohort of the TEAM trial. Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:1 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Postmenopause; Retrospective Studies; Survival Rate; Tamoxifen	2014
External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:4 Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Netherlands; Odds Ratio; Receptors, Estrogen; Receptors, Progesterone; Registries; Reproducibility of Results; Tamoxifen; Treatment Outcome	2014
Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study. Cancer, 2014, Sep-15, Volume: 120, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Exercise; Female; Follow-Up Studies; Humans; Life Style; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen	2014
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. The New England journal of medicine, 2014, Jul-10, Volume: 371, Issue:2 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Osteoporosis; Premenopause; Quality of Life; Tamoxifen; Triptorelin Pamoate	2014
Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis. Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:3 Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Density; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Mammary Glands, Human; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Radiography; Tamoxifen; Treatment Outcome	2015
Adjuvant ovarian suppression in premenopausal breast cancer. The New England journal of medicine, 2015, Jan-29, Volume: 372, Issue:5 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Mastectomy; Middle Aged; Premenopause; Tamoxifen	2015
Does patient education work in breast cancer? Final results from the global CARIATIDE study. Future oncology (London, England), 2015, Volume: 11, Issue:2 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles	2015
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast cancer research and treatment, 2015, Volume: 149, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Forkhead Transcription Factors; Histocompatibility Antigens Class I; HLA-E Antigens; HLA-G Antigens; Humans; Immunophenotyping; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Receptors, Estrogen; T-Lymphocytes, Regulatory; Tamoxifen	2015
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:9 Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor beta; Female; Humans; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Tamoxifen; Treatment Outcome	2015
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast cancer research and treatment, 2015, Volume: 152, Issue:3 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles	2015
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Archives of pathology & laboratory medicine, 2016, Volume: 140, Issue:1 Topics: Algorithms; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorescent Antibody Technique; Humans; Image Interpretation, Computer-Assisted; Immunohistochemistry; Kaplan-Meier Estimate; Prognosis; Tamoxifen; Treatment Outcome	2016
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-10, Volume: 34, Issue:14 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estradiol; Estrogens; Estrone; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Ovary; Tamoxifen; Triptorelin Pamoate	2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-10, Volume: 34, Issue:14 Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Ovary; Premenopause; Quality of Life; Self Report; Tamoxifen; Triptorelin Pamoate	2016
Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Aug-01, Volume: 35, Issue:22 Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptors, Estrogen; Survival Rate; Tamoxifen; Time Factors	2017
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:9 Topics: Adenocarcinoma; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mastectomy; Middle Aged; Postmenopause; Tamoxifen; Time Factors; Treatment Outcome	2017
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast cancer research and treatment, 2018, Volume: 168, Issue:1 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors	2018
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. The Lancet. Oncology, 2018, Volume: 19, Issue:4 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen	2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. Oncology research and treatment, 2018, Volume: 41, Issue:3 Topics: Androstadienes; Breast Neoplasms; Female; Humans; Neoplastic Cells, Circulating; Postmenopause; Tamoxifen	2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. The New England journal of medicine, 2018, Jul-12, Volume: 379, Issue:2 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Premenopause; Receptor, ErbB-2; Tamoxifen; Young Adult	2018
Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. European journal of cancer (Oxford, England : 1990), 2018, Volume: 99 Topics: Age Factors; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cause of Death; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen	2018
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. Journal of the National Cancer Institute, 2018, 06-01, Volume: 110, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Postmenopause; Prognosis; Retrospective Studies; Tamoxifen; Treatment Outcome	2018
Effects of Pharmacogenomics, 2019, Volume: 20, Issue:8 Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogens; Female; Genotype; Humans; Letrozole; Liver-Specific Organic Anion Transporter 1; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen	2019

Other Studies

125 other study(ies) available for aromasil and tamoxifen

Article	Year
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. The Journal of steroid biochemistry and molecular biology, 1993, Volume: 44, Issue:4-6 Topics: 9,10-Dimethyl-1,2-benzanthracene; Adrenal Glands; Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Drug Synergism; Female; Mammary Neoplasms, Experimental; Organ Size; Ovary; Pituitary Gland; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus	1993
Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast cancer research and treatment, 1995, Volume: 36, Issue:3 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dexamethasone; Enzyme Inhibitors; Female; Humans; Lipids; Magnetic Resonance Spectroscopy; Tamoxifen	1995
Longer time to tumor progression with exemestane vs tamoxifen in advanced breast cancer. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:9 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Tamoxifen	2000
Aromatase inhibitors and inactivators in breast cancer. BMJ (Clinical research ed.), 2001, Oct-20, Volume: 323, Issue:7318 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles	2001
The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Incidence; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; White People	2001
New breast cancer drugs expand treatment options. Harvard women's health watch, 2002, Volume: 9, Issue:8 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles	2002
Estrogen as therapy for breast cancer. Breast cancer research : BCR, 2002, Volume: 4, Issue:4 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles	2002
Current role of endocrine therapy in the management of breast cancer. Breast cancer (Tokyo, Japan), 2002, Volume: 9, Issue:4 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles	2002
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:3-5 Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cell Line, Tumor; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles	2003
Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 2 Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Female; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen	2004
Neoadjuvant endocrine therapy as a drug development strategy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 2 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Celecoxib; Clinical Trials as Topic; Drug Design; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Pyrazoles; Signal Transduction; Sulfonamides; Tamoxifen	2004
New stars in the sky of treatment for early breast cancer. The New England journal of medicine, 2004, Mar-11, Volume: 350, Issue:11 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Tamoxifen	2004
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer. European journal of gynaecological oncology, 2004, Volume: 25, Issue:1 Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A	2004
Tamoxifen shuffle. Health news (Waltham, Mass.), 2004, Volume: 10, Issue:5 Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen	2004
Adjuvant treatment of breast cancer with exemestane. The New England journal of medicine, 2004, Jul-01, Volume: 351, Issue:1 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Radiotherapy, Adjuvant; Tamoxifen	2004
Adjuvant treatment of breast cancer with exemestane. The New England journal of medicine, 2004, Jul-01, Volume: 351, Issue:1 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Female; Humans; Tamoxifen	2004
Adjuvant treatment of breast cancer with exemestane. The New England journal of medicine, 2004, Jul-01, Volume: 351, Issue:1 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Osteoporosis; Tamoxifen	2004
Exemestane following tamoxifen in postmenopausal women with primary breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18 Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Risk Factors; Tamoxifen	2004
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-01, Volume: 10, Issue:21 Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Random Allocation; Tamoxifen; Time Factors; Triazoles	2004
[New results of endocrine therapy of breast cancer (the role of Aromasin)]. Voprosy onkologii, 2004, Volume: 50, Issue:6 Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Tamoxifen; Treatment Outcome	2004
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells]. MMW Fortschritte der Medizin, 2005, Mar-10, Volume: 147, Issue:10 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles	2005
Aromatase inhibitors: cellular and molecular effects. The Journal of steroid biochemistry and molecular biology, 2005, Volume: 95, Issue:1-5 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles	2005
Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer? Nature clinical practice. Oncology, 2004, Volume: 1, Issue:1 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen	2004
Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-20, Volume: 24, Issue:6 Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Patient Satisfaction; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome	2006
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2005, Volume: 59 Suppl 2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles	2005
A 62-year-old woman with a new diagnosis of breast cancer. JAMA, 2006, Mar-22, Volume: 295, Issue:12 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Decision Making; Female; Humans; Mastectomy, Segmental; Middle Aged; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen	2006
Does survival increase in metastatic breast cancer with recently available anticancer drugs? Oncology research, 2006, Volume: 15, Issue:9 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles	2006
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles	2006
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles	2006
Management of choroidal metastases from breast carcinomas using aromatase inhibitors. Current opinion in ophthalmology, 2006, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles	2006
Can switching treatments improve breast-cancer outcome? The Lancet. Oncology, 2006, Volume: 7, Issue:7 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Tamoxifen	2006
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast cancer research and treatment, 2007, Volume: 101, Issue:3 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States	2007
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. Breast (Edinburgh, Scotland), 2007, Volume: 16, Issue:3 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles	2007
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Nitriles; Remission Induction; Tamoxifen; Triazoles	2007
Optimising bone health in survivors of breast cancer. The Lancet. Oncology, 2007, Volume: 8, Issue:2 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Density; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Female; Humans; Postmenopause; Survivors; Tamoxifen	2007
Cancer: some reasons to be hopeful. Lancet (London, England), 2007, Feb-17, Volume: 369, Issue:9561 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Tamoxifen	2007
Switching to aromatase inhibitors in early breast cancer. Lancet (London, England), 2007, Feb-17, Volume: 369, Issue:9561 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen	2007
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast (Edinburgh, Scotland), 2007, Volume: 16, Issue:5 Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles	2007
Exemestane or tamoxifen? Lancet (London, England), 2007, May-12, Volume: 369, Issue:9573 Topics: Androstadienes; Aromatase Inhibitors; Cardiovascular Diseases; Follow-Up Studies; Humans; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Exemestane or tamoxifen? Lancet (London, England), 2007, May-12, Volume: 369, Issue:9573 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Postmenopause; Tamoxifen	2007
Exemestane or tamoxifen? Lancet (London, England), 2007, May-12, Volume: 369, Issue:9573 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Survival Analysis; Tamoxifen	2007
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer, 2007, Aug-01, Volume: 110, Issue:3 Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Quality-Adjusted Life Years; SEER Program; Selective Estrogen Receptor Modulators; Sensitivity and Specificity; Survival Rate; Tamoxifen	2007
Chemoprevention of breast cancer. Breast cancer (Tokyo, Japan), 2008, Volume: 15, Issue:1 Topics: Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2008
Update: a 62-year-old woman with a new diagnosis of breast cancer. JAMA, 2008, Mar-05, Volume: 299, Issue:9 Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Tamoxifen	2008
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Female; Goserelin; Humans; Premenopause; Randomized Controlled Trials as Topic; Tamoxifen	2008
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward. Anti-cancer drugs, 2008, Volume: 19 Suppl 2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles	2008
Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast cancer research and treatment, 2008, Volume: 112, Issue:3 Topics: Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Receptors, Estrogen; Tamoxifen	2008
Intergroup Exemestane Study mature analysis: overall survival data. Anti-cancer drugs, 2008, Volume: 19 Suppl 1 Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen	2008
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug metabolism reviews, 2010, Volume: 42, Issue:1 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles	2010
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. The Journal of steroid biochemistry and molecular biology, 2010, Feb-28, Volume: 118, Issue:4-5 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles	2010
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:13 Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Letrozole; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Toremifene; Triazoles	2009
Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Critical reviews in oncology/hematology, 2010, Volume: 76, Issue:2 Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Comorbidity; Diabetes Mellitus; Female; Humans; Hypertension; Intelligence Tests; Middle Aged; Multicenter Studies as Topic; Neuropsychological Tests; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen	2010
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-10, Volume: 28, Issue:8 Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Female; Humans; Middle Aged; Netherlands; Postmenopause; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2010
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. The British journal of surgery, 2010, Volume: 97, Issue:5 Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Clinical Protocols; Combined Modality Therapy; Epidemiologic Methods; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Patient Selection; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen	2010
Differential diagnosis of lung nodules: breast cancer metastases and lung tuberculosis. Le infezioni in medicina, 2010, Volume: 18, Issue:1 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Diagnosis, Differential; Estrogens; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasms, Hormone-Dependent; Progesterone; Recurrence; Tamoxifen; Tomography, X-Ray Computed; Tuberculosis, Pulmonary	2010
Death due to liver failure during endocrine therapy for premenopausal breast cancer. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:6 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Diphenhydramine; Drug Synergism; Estrogen Receptor Modulators; Fatal Outcome; Female; Hepatitis, Alcoholic; Humans; Hypnotics and Sedatives; Liver Failure, Acute; Middle Aged; Premenopause; Self Medication; Tamoxifen; Triptorelin Pamoate	2010
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. British journal of cancer, 2010, Jul-27, Volume: 103, Issue:3 Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Case-Control Studies; Cytokines; Estrogens; Female; Humans; Inflammation; Middle Aged; Musculoskeletal Diseases; Postmenopause; Syndrome; Tamoxifen; Taxoids	2010
Cognitive changes associated with endocrine therapy for breast cancer. Maturitas, 2010, Volume: 67, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health	2010
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:16 Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Middle Aged; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles	2010
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles	2010
Time to TEAM: exemestane, or tamoxifen then exemestane? Lancet (London, England), 2011, Jan-22, Volume: 377, Issue:9762 Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Translational Research, Biomedical	2011
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8 Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles	2011
Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psycho-oncology, 2012, Volume: 21, Issue:5 Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Depression; Female; Humans; Middle Aged; Neuropsychological Tests; Postmenopause; Prospective Studies; Randomized Controlled Trials as Topic; Self Report; Surveys and Questionnaires; Tamoxifen	2012
Examination of the use of Exemestane in patients with metastatic breast cancer. Breast cancer (Tokyo, Japan), 2011, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Medroxyprogesterone Acetate; Middle Aged; Retrospective Studies; Tamoxifen	2011
Estrogen and progesterone receptors in breast cancer. Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:5 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Female; Humans; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen	2011
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. American journal of clinical pathology, 2011, Volume: 136, Issue:2 Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Female; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Practice Guidelines as Topic; Prognosis; Tamoxifen; Treatment Outcome	2011
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer? Annals of the Royal College of Surgeons of England, 2011, Volume: 93, Issue:4 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles	2011
The breast cancer chemoprevention debate. Journal of the National Cancer Institute, 2011, Nov-16, Volume: 103, Issue:22 Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2011
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. Annals of surgical oncology, 2012, Volume: 19, Issue:4 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles	2012
Aromatase inhibitors and musculoskeletal adverse events. The Lancet. Oncology, 2012, Volume: 13, Issue:4 Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Female; Humans; Musculoskeletal Abnormalities; Tamoxifen	2012
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-01, Volume: 30, Issue:7 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles	2012
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA, 2012, Feb-08, Volume: 307, Issue:6 Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cause of Death; Female; Follow-Up Studies; Humans; Middle Aged; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk; Tamoxifen	2012
Exemestane for primary prevention of breast cancer in postmenopausal women. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Aug-15, Volume: 69, Issue:16 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2012
Prognostic/Predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: back to the future? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Dec-20, Volume: 30, Issue:36 Topics: Androstadienes; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Tamoxifen; Tissue Array Analysis	2012
Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3 Topics: Adult; Amenorrhea; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Substitution; Estradiol; Female; Humans; Incidence; Kaplan-Meier Estimate; Menstruation; Middle Aged; Ovary; Prospective Studies; Recovery of Function; ROC Curve; Tamoxifen; Treatment Outcome	2013
The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast cancer research and treatment, 2012, Volume: 136, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoprevention; Female; Humans; Hyperplasia; Mammary Glands, Human; Middle Aged; Precancerous Conditions; Raloxifene Hydrochloride; Tamoxifen	2012
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles	2013
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-20, Volume: 31, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Genital Diseases, Female; Humans; International Cooperation; Middle Aged; Multicenter Studies as Topic; Musculoskeletal Diseases; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Vasomotor System	2013
Treatment-emergent effects may predict benefit from endocrine therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-20, Volume: 31, Issue:18 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Mammary Glands, Human; Outcome Assessment, Health Care; Postmenopause; Tamoxifen	2013
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. Annals of surgical oncology, 2014, Volume: 21, Issue:5 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles	2014
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles	2014
VAV3 mediates resistance to breast cancer endocrine therapy. Breast cancer research : BCR, 2014, May-28, Volume: 16, Issue:3 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles	2014
Hormone therapy in premenopausal women with early-stage breast cancer. The New England journal of medicine, 2014, Jul-10, Volume: 371, Issue:2 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Tamoxifen; Triptorelin Pamoate	2014
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-20, Volume: 32, Issue:27 Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Tamoxifen	2014
A new combination therapy for premenopausal breast cancer. The Lancet. Oncology, 2014, Volume: 15, Issue:8 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Premenopause; Tamoxifen	2014
More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care. Cancer, 2014, Oct-01, Volume: 120, Issue:19 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Estrogen Receptor Modulators; Evidence-Based Medicine; Female; Humans; Neoplasm Staging; Ovary; Postmenopause; Practice Guidelines as Topic; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen	2014
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:1 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles	2015
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience. Gynecologic and obstetric investigation, 2015, Volume: 80, Issue:1 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles	2015
Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains. The New England journal of medicine, 2015, Jan-29, Volume: 372, Issue:5 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Tamoxifen; Triptorelin Pamoate	2015
Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be repurposed for breast cancer therapy. Computers in biology and medicine, 2015, Volume: 61 Topics: Androstadienes; Breast Neoplasms; Databases, Genetic; Female; Gene Ontology; Humans; Pharmacogenetics; Prognosis; Tamoxifen	2015
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. International journal of oncology, 2015, Volume: 46, Issue:4 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles	2015
Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2015, Jun-16, Volume: 187, Issue:9 Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Chemoprevention; Female; Humans; Middle Aged; Risk Assessment; Tamoxifen	2015
Breast cancer risk reduction therapy: the low-hanging fruit. Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:4 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2015
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study. Journal of affective disorders, 2015, Aug-15, Volume: 182 Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles	2015
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line. Oncology, 2015, Volume: 89, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles	2015
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nature communications, 2016, Feb-09, Volume: 7 Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles	2016
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 07-01, Volume: 34, Issue:19 Topics: Adult; Aged; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovary; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen	2016
Adjuvant endocrine therapy in premenopausal women with breast cancer. Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:10 Topics: Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Hormone Replacement Therapy; Humans; Middle Aged; Postmenopause; Quality of Life; Tamoxifen	2015
Are SOFT and TEXT results practice changing and how? Breast (Edinburgh, Scotland), 2016, Volume: 27 Topics: Adult; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Ovary; Premenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen	2016
[Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2016, May-23, Volume: 38, Issue:5 Topics: Adjuvants, Immunologic; Adult; Age Factors; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Ovary; Premenopause; Tamoxifen	2016
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study. Breast (Edinburgh, Scotland), 2016, Volume: 28 Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Radiotherapy; Rats; Rats, Wistar; Tamoxifen; Triazoles	2016
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study. The Journal of steroid biochemistry and molecular biology, 2017, Volume: 169 Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neoplasms; Cholestanes; Cholesterol; Feasibility Studies; Female; Gas Chromatography-Mass Spectrometry; Hormones; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Oxidative Stress; Oxysterols; Pilot Projects; Prognosis; Prospective Studies; Reproducibility of Results; Signal Transduction; Tamoxifen; Triazoles	2017
Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Annals of internal medicine, 2016, 08-02, Volume: 165, Issue:3 Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Humans; Middle Aged; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen	2016
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor. Medical hypotheses, 2017, Volume: 101 Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A	2017
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 08-01, Volume: 28, Issue:8 Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gene Amplification; Goserelin; Humans; Piperazines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases	2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Sep-20, Volume: 35, Issue:27 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Premenopause; Quality of Life; Receptor, ErbB-2; Tamoxifen; Treatment Outcome	2017
Adjuvant endocrine therapy for premenopausal women: Type and duration. Breast (Edinburgh, Scotland), 2017, Volume: 34 Suppl 1 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Premenopause; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Time Factors	2017
Tuning up adjuvant endocrine therapy: the TEAM trial. The Lancet. Oncology, 2017, Volume: 18, Issue:9 Topics: Androstadienes; Breast Neoplasms; Female; Follow-Up Studies; Humans; Postmenopause; Tamoxifen	2017
Adjuvant aromatase inhibition: more options for patients. The Lancet. Oncology, 2018, Volume: 19, Issue:4 Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen	2018
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC cancer, 2018, Oct-12, Volume: 18, Issue:1 Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome	2018
Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019, Feb-01, Volume: 1106-1107 Topics: Administration, Oral; Anastrozole; Androstadienes; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Nitriles; Phenylthiohydantoin; Tamoxifen; Tandem Mass Spectrometry; Tosyl Compounds	2019
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. Breast cancer research and treatment, 2019, Volume: 175, Issue:1 Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasm Grading; Neoplasm Staging; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Tamoxifen; Treatment Outcome	2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B172 gene deletion. Breast cancer research and treatment, 2019, Volume: 175, Issue:2* Topics: Androstadienes; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Gene Deletion; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Letrozole; Middle Aged; Minor Histocompatibility Antigens; Pharmacogenetics; Postmenopause; Tamoxifen	2019
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues. The breast journal, 2019, Volume: 25, Issue:6 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Drug Monitoring; Estradiol; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Function Tests; Ovary; Premenstrual Syndrome; Tamoxifen; Uterine Hemorrhage	2019
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider. Journal of women's health (2002), 2020, Volume: 29, Issue:1 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Making, Shared; Female; Humans; Middle Aged; Physician-Patient Relations; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2020
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 04-20, Volume: 38, Issue:12 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovariectomy; Ovary; Premenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triptorelin Pamoate	2020
Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. Breast (Edinburgh, Scotland), 2019, Volume: 48 Suppl 1 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovary; Premenopause; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; Time Factors; Young Adult	2019
Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer. Pharmacogenomics, 2020, Volume: 21, Issue:9 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Genome-Wide Association Study; Genomics; Germ Cells; Humans; Selective Estrogen Receptor Modulators; Tamoxifen	2020
Breast Cancer Risk-Reducing Medications. JAMA, 2020, 07-21, Volume: 324, Issue:3 Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2020
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 10-01, Volume: 38, Issue:28 Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Tamoxifen	2020
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL). Cancer research and treatment, 2021, Volume: 53, Issue:3 Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen	2021
Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts? JNCI cancer spectrum, 2023, 03-01, Volume: 7, Issue:2 Topics: Breast Neoplasms; Cognition; Female; Humans; Postmenopause; Tamoxifen	2023
Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer. JNCI cancer spectrum, 2023, 03-01, Volume: 7, Issue:2 Topics: Breast Neoplasms; Cognition; Female; Follow-Up Studies; Humans; Postmenopause; Prospective Studies; Tamoxifen	2023